BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36149789)

  • 21. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
    Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
    Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
    Fujii K; Miyata Y; Takahashi I; Koizumi H; Saji H; Hoshikawa M; Takagi M; Nishimura T; Nakamura H
    Proteomics Clin Appl; 2018 Nov; 12(6):e1800015. PubMed ID: 29888431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
    Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR; Curran WJ; Ivanov AA; Fu H; Lonial S; Ramalingam SS; Sun SY; Waller EK; Sica GL
    J Thorac Oncol; 2021 Mar; 16(3):464-476. PubMed ID: 33248321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular subtypes, predictive markers and prognosis in small-cell lung carcinoma.
    Zhu Y; Li S; Wang H; Ren W; Chi K; Wu J; Mao L; Huang X; Zhuo M; Lin D
    J Clin Pathol; 2023 Sep; ():. PubMed ID: 37775262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
    Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
    Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
    Gay CM; Stewart CA; Park EM; Diao L; Groves SM; Heeke S; Nabet BY; Fujimoto J; Solis LM; Lu W; Xi Y; Cardnell RJ; Wang Q; Fabbri G; Cargill KR; Vokes NI; Ramkumar K; Zhang B; Della Corte CM; Robson P; Swisher SG; Roth JA; Glisson BS; Shames DS; Wistuba II; Wang J; Quaranta V; Minna J; Heymach JV; Byers LA
    Cancer Cell; 2021 Mar; 39(3):346-360.e7. PubMed ID: 33482121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
    Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K
    EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative proteomic analysis of bronchoalveolar lavage fluids from patients with small cell lung cancers.
    Vu HM; Mohammad HB; Nguyen TNC; Lee JH; Do Y; Sung JY; Lee SH; Kim MS
    Proteomics Clin Appl; 2023 Sep; 17(5):e2300011. PubMed ID: 36807835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Killing SCLC: insights into how to target a shapeshifting tumor.
    Sutherland KD; Ireland AS; Oliver TG
    Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heterogeneity of small cell lung cancer: biological and clinicopathological implications].
    Megyesfalvi Z; Bárány N; Valkó Z; Bugyik E; Paku S; Berta J; Lantos A; Fillinger J; Moldvay J; Bogos K; Rezeli M; Gálffy G; Lang C; Lohinai Z; Hécz R; Lovas T; Rényi-Vámos F; László V; Döme B
    Magy Onkol; 2020 Sep; 64(3):243-255. PubMed ID: 34608895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small cell lung cancer - news in the tumour´s biology.
    Pavlíčková K; Matěj R
    Cesk Patol; 2023; 59(1):18-22. PubMed ID: 37072275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
    Rudin CM; Poirier JT; Byers LA; Dive C; Dowlati A; George J; Heymach JV; Johnson JE; Lehman JM; MacPherson D; Massion PP; Minna JD; Oliver TG; Quaranta V; Sage J; Thomas RK; Vakoc CR; Gazdar AF
    Nat Rev Cancer; 2019 May; 19(5):289-297. PubMed ID: 30926931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. YAP1 expression is associated with survival and immunosuppression in small cell lung cancer.
    Chen P; Sun C; Wang H; Zhao W; Wu Y; Guo H; Zhou C; He Y
    Cell Death Dis; 2023 Sep; 14(9):636. PubMed ID: 37752152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
    Pearsall SM; Humphrey S; Revill M; Morgan D; Frese KK; Galvin M; Kerr A; Carter M; Priest L; Blackhall F; Simpson KL; Dive C
    J Thorac Oncol; 2020 Dec; 15(12):1836-1843. PubMed ID: 32721553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
    Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
    Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
    Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
    Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer.
    Huang YH; Klingbeil O; He XY; Wu XS; Arun G; Lu B; Somerville TDD; Milazzo JP; Wilkinson JE; Demerdash OE; Spector DL; Egeblad M; Shi J; Vakoc CR
    Genes Dev; 2018 Jul; 32(13-14):915-928. PubMed ID: 29945888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy.
    Shirasawa M; Yoshida T; Shiraishi K; Takigami A; Takayanagi D; Imabayashi T; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yotsukura M; Yoshida Y; Nakagawa K; Tsuchida T; Hamamoto R; Yamamoto N; Motoi N; Kohno T; Watanabe SI; Ohe Y
    Lung Cancer; 2023 May; 179():107183. PubMed ID: 37037178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.